Table of Contents

• Overview of (2S,3R,4R,5S)-1-[5-(2-FLUORO-BIPHENYL-4-YLMETHOXY)-PENTYL]-2-HYDROXYMETHYL-PIPERIDINE-3,4,5-TRIOL Research
• Phase 1 ADME Study Design
• Study Objectives and Endpoints
• Methodology and Radiotracer Approach
• Participant Characteristics and Enrollment
• Clinical Significance of ADME Studies

Overview of (2S,3R,4R,5S)-1-[5-(2-FLUORO-BIPHENYL-4-YLMETHOXY)-PENTYL]-2-HYDROXYMETHYL-PIPERIDINE-3,4,5-TRIOL Research

(2S,3R,4R,5S)-1-[5-(2-FLUORO-BIPHENYL-4-YLMETHOXY)-PENTYL]-2-HYDROXYMETHYL-PIPERIDINE-3,4,5-TRIOL, also designated as AZ-3102, is an investigational compound currently undergoing clinical evaluation^[1]. The substance is in early-stage development, with research focused on understanding its fundamental pharmacokinetic properties before advancing to later-phase efficacy and safety trials.

A completed Phase 1 clinical trial has examined the absorption, metabolism, and excretion (ADME) characteristics of this compound in healthy human volunteers^[1]. ADME studies represent a critical component of drug development, providing essential information about how a substance behaves in the human body. These studies help researchers understand the complete journey of a drug from administration through elimination, which informs dosing strategies and identifies potential safety considerations for future clinical development.

The clinical trial investigating (2S,3R,4R,5S)-1-[5-(2-FLUORO-BIPHENYL-4-YLMETHOXY)-PENTYL]-2-HYDROXYMETHYL-PIPERIDINE-3,4,5-TRIOL employed advanced radiotracer methodology to precisely track the compound’s fate in the human body^[1]. This approach allows researchers to account for all drug-related material and identify the chemical forms into which the original compound is transformed.

Phase 1 ADME Study Design

The clinical trial investigating (2S,3R,4R,5S)-1-[5-(2-FLUORO-BIPHENYL-4-YLMETHOXY)-PENTYL]-2-HYDROXYMETHYL-PIPERIDINE-3,4,5-TRIOL was designed as an open-label, single-dose Phase 1 study^[1]. In an open-label design, both researchers and participants are aware of the treatment being administered, which is appropriate for this type of fundamental pharmacokinetic research where blinding offers no scientific advantage.

The study utilized a single-dose administration approach, which is standard for ADME investigations^[1]. This design allows researchers to track the complete lifecycle of a single dose through the body without the complicating factors of repeated dosing or drug accumulation. Participants received a carefully controlled amount of the substance, enabling precise measurement of its absorption, distribution, metabolism, and excretion.

The trial was conducted with 7 healthy male subjects, representing a typical enrollment size for this type of specialized metabolic study^[1]. The relatively small sample size is scientifically appropriate because ADME studies using radioactive tracers generate highly detailed, quantitative data from each participant. The focus on healthy male volunteers is characteristic of early Phase 1 metabolism studies, which aim to establish baseline pharmacokinetic parameters in individuals without confounding medical conditions or medications.

The study has been completed, indicating that all participants have finished the protocol procedures and sample collection has been finalized^[1]. The completion status suggests that data analysis is underway or finished, providing valuable information about how the human body handles this investigational compound.

Study Objectives and Endpoints

The clinical trial investigating (2S,3R,4R,5S)-1-[5-(2-FLUORO-BIPHENYL-4-YLMETHOXY)-PENTYL]-2-HYDROXYMETHYL-PIPERIDINE-3,4,5-TRIOL had three primary scientific objectives that together provide a comprehensive understanding of the compound’s pharmacokinetic behavior^[1].

Mass Balance Determination

The first major objective was to determine the routes and rates of elimination of drug-related materials by assessing mass balance^[1]. This involved measuring the cumulative excretion of total radioactivity in urine and feces following administration of the radiolabeled compound. Mass balance studies answer fundamental questions about where administered drug material goes: how much is eliminated through urine versus feces, how quickly elimination occurs, and what percentage of the administered dose can be accounted for in excreta.

Understanding elimination routes is crucial for predicting how the drug might behave in patients with kidney or liver impairment. If a substance is primarily eliminated through urine, patients with kidney disease might require dose adjustments. Conversely, if elimination occurs mainly through feces via bile, liver function becomes the critical consideration.

Metabolic Profiling

The second objective focused on assessing the metabolic profile of AZ-3102 in plasma, urine, and feces^[1]. Metabolic profiling involves identifying and quantifying all the different chemical forms that result when the body’s enzymes break down the original compound. This analysis is conducted in multiple biological matrices:

• Plasma analysis reveals which metabolites circulate in the bloodstream and might contribute to drug effects or interact with other medications
• Urine analysis identifies metabolites eliminated through the kidneys, providing insight into renal clearance pathways
• Feces analysis captures metabolites eliminated through the bile and digestive tract, indicating hepatic processing

Comprehensive metabolic profiling helps researchers understand whether the parent compound or its metabolites are responsible for biological activity, and whether any metabolites might raise safety concerns that require further investigation.

Pharmacokinetic Characterization

The third objective was to characterize the pharmacokinetics of total radioactivity in applicable matrices^[1]. This involves measuring how concentrations of drug-related material change over time in blood, plasma, urine, and feces. Key pharmacokinetic parameters typically include:

• Maximum concentration (Cmax) and when it occurs (Tmax)
• Area under the concentration-time curve (AUC), representing total drug exposure
• Half-life (t½), indicating how long the substance remains in the body
• Clearance rates from different body compartments
• Volume of distribution, suggesting how widely the compound disperses throughout body tissues

These pharmacokinetic parameters form the foundation for determining appropriate dosing regimens in later clinical trials and eventual therapeutic use.

Methodology and Radiotracer Approach

The study employed a sophisticated radiotracer methodology using carbon-14 labeled (2S,3R,4R,5S)-1-[5-(2-FLUORO-BIPHENYL-4-YLMETHOXY)-PENTYL]-2-HYDROXYMETHYL-PIPERIDINE-3,4,5-TRIOL, designated as [14C]-AZ-3102^[1]. This approach involves incorporating a radioactive carbon-14 atom into the molecular structure of the compound, creating a version that behaves identically to the non-radioactive form but can be precisely tracked using radiation detection equipment.

Dosing Parameters

Participants received a single oral dose of 9 mg of [14C]-AZ-3102 containing approximately 3.7 MBq (100 μCi) of radioactivity^[1]. This radioactivity level is carefully selected to be:

• High enough to allow sensitive detection and accurate quantification of drug material throughout the body and in excreta
• Low enough to pose minimal radiation exposure risk to participants, well within established safety limits for research studies
• Standardized according to regulatory guidelines for human radiolabeled drug studies

The compound was administered as an oral solution, ensuring consistent and complete delivery of the dose^[1]. Liquid formulations are often preferred in ADME studies because they eliminate variability related to tablet dissolution or capsule disintegration, providing more precise pharmacokinetic data.

Sample Collection and Analysis

Following administration of [14C]-AZ-3102, researchers collected multiple types of biological samples to track the compound’s journey through the body^[1]. The study protocol involved systematic collection of:

• Blood and plasma samples at multiple time points to measure drug concentrations and identify circulating metabolites
• Complete urine collections over extended periods to quantify renal elimination and identify urinary metabolites
• Complete fecal collections to measure biliary/intestinal elimination and characterize fecal metabolites

The radioactive label allows researchers to measure total drug-related radioactivity in each sample using liquid scintillation counting, a highly sensitive technique that can detect extremely low levels of carbon-14. Additionally, sophisticated analytical chemistry methods such as high-performance liquid chromatography with radioactivity detection (HPLC-RAD) and mass spectrometry enable identification and quantification of the parent compound and all its metabolites.

Participant Characteristics and Enrollment

The study enrolled 7 healthy male subjects, a participant population carefully selected to meet the scientific objectives of this Phase 1 ADME investigation^[1]. The choice of healthy volunteers rather than patients reflects the study’s focus on fundamental pharmacokinetic characterization rather than therapeutic efficacy.

Rationale for Healthy Volunteers

Using healthy participants in Phase 1 ADME studies offers several scientific advantages. Healthy volunteers provide baseline pharmacokinetic data without the confounding effects of disease states, comedications, or altered organ function. This approach allows researchers to understand how the compound behaves in normal human physiology, establishing reference values against which later studies in patient populations can be compared.

Additionally, healthy volunteers can typically tolerate the study procedures more easily, including the extended confinement often required for complete urine and fecal collection in radiotracer studies. The absence of underlying medical conditions also reduces safety concerns when administering a novel compound for the first time in humans.

Male-Only Population

The restriction to male subjects is common in early Phase 1 metabolism studies for several reasons. This approach eliminates pharmacokinetic variability related to menstrual cycle hormonal fluctuations in women. It also avoids any theoretical risk to potentially pregnant women, even though participants undergo pregnancy testing and use contraception. As drug development progresses, subsequent studies specifically examine pharmacokinetics in women and assess whether gender differences require dosing adjustments.

Sample Size Considerations

The enrollment of 7 participants represents an appropriate sample size for this type of specialized metabolic investigation. ADME studies using radioactive tracers generate extensive quantitative data from each individual, including complete mass balance accounting and comprehensive metabolic profiling. The detailed, mechanistic nature of this data means that relatively small sample sizes can provide statistically robust and scientifically meaningful results. Regulatory agencies recognize that 6-8 participants typically suffice for human ADME studies when radiotracer methodology is employed.

Clinical Significance of ADME Studies

The completed Phase 1 ADME study of (2S,3R,4R,5S)-1-[5-(2-FLUORO-BIPHENYL-4-YLMETHOXY)-PENTYL]-2-HYDROXYMETHYL-PIPERIDINE-3,4,5-TRIOL represents a critical milestone in the development of this investigational compound^[1]. ADME studies provide foundational knowledge that guides all subsequent clinical development decisions.

Impact on Drug Development Strategy

The results from this study will inform multiple aspects of future clinical trials. Understanding the routes of elimination helps researchers predict which patient populations might require dose adjustments. If the compound is primarily eliminated through the kidneys, patients with renal impairment will need special dosing considerations. If elimination occurs mainly through the liver, hepatic impairment becomes the key concern.

Knowledge of the metabolic profile reveals whether the parent compound or its metabolites are likely responsible for therapeutic effects or potential side effects. If active metabolites are identified, researchers must consider their contribution to overall drug activity. If potentially toxic metabolites are found, additional safety studies may be required.

The pharmacokinetic parameters established in this study provide the basis for selecting appropriate doses and dosing frequencies in later efficacy trials. Understanding how long the drug remains in the body helps determine whether once-daily, twice-daily, or other dosing schedules are most appropriate.

Regulatory Requirements

ADME studies using radiolabeled compounds are typically required by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) as part of the standard drug development process. These studies provide data that regulatory reviewers use to assess whether a new drug can be safely administered to patients and to establish appropriate labeling regarding dosing in special populations.

The mass balance data from this study will be particularly important for regulatory submissions, as agencies require documentation of how much of an administered dose can be accounted for and through which routes elimination occurs. Complete mass balance recovery (typically >90% of the administered dose) provides confidence that the drug’s fate in the body is well understood.

Foundation for Future Research

With the completion of this Phase 1 ADME study, the development program for (2S,3R,4R,5S)-1-[5-(2-FLUORO-BIPHENYL-4-YLMETHOXY)-PENTYL]-2-HYDROXYMETHYL-PIPERIDINE-3,4,5-TRIOL can progress to subsequent phases of clinical investigation^[1]. The pharmacokinetic knowledge gained from this trial will support the design of Phase 2 studies examining therapeutic efficacy in patient populations with specific diseases or conditions.

Future studies may explore drug-drug interactions, examine pharmacokinetics in special populations such as elderly patients or those with organ impairment, and evaluate the compound’s safety and efficacy across different patient groups. Each of these subsequent investigations will build upon the fundamental ADME data established in this completed Phase 1 trial.